Health your username 6 days ago The Second Circuit on Tuesday affirmed a Southern District of New York dismissal of a case brought by 71 individuals against Taro Pharmaceutical U.S.A. Inc. lodging claims of strict liability, negligent failure to warn, negligent marketing and sale, negligence per se, fraud, and wrongful death stemming from the plaintiffs’ use of Taro drug Amiodarone. The original complaint against generic pharmaceutical manufacturer Taro alleged that the drug company was complicit in the injuries of the plaintiffs, some purportedly resulting in death, by failing to make “medication guides” noting proper use and risks of Amiodarone available to patients and failing to ensure that the drug information promulgated to physicians was accurate. The plaintiffs also claimed that Taro “concealed” records of adverse effects of the drug in treating atrial fibrillation.